Search

Your search keyword '"Fredriksson, Martin"' showing total 257 results

Search Constraints

Start Over You searched for: Author "Fredriksson, Martin" Remove constraint Author: "Fredriksson, Martin"
257 results on '"Fredriksson, Martin"'

Search Results

3. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial

4. CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research

6. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

8. Authors, Inventors and Entrepreneurs: Intellectual Property and Actors of Extraction

10. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes

12. Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58

13. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58

15. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes A Secondary Analysis of the DECLARE-TIMI 58 Trial

16. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction: Subanalysis From the DECLARE-TIMI 58 Trial

18. Epilogue

21. CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research

22. CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research

23. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial

25. Online Engineering and Open Computational Systems

26. Sustainable Coordination

27. Sustainable Information Ecosystems

32. Open Source Seeds and the Revitalization of Local Knowledge

33. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.

35. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

37. Welcome to the party

38. Political Parties and Organization Studies: The party as a critical case of organizing.

40. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58

43. Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58

45. Balancing community rights and national interests in international protection of traditional knowledge: a study of India's Traditional Knowledge Digital Library.

47. 303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial

48. 1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58

49. Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study

50. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study

Catalog

Books, media, physical & digital resources